Chardan Capital comments on Dyne Therapeutics, Inc.’s 2024 earnings. (NASDAQ:DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) – Research analysts at Chardan Capital reduced their FY2024 EPS estimates for shares of Dyne Therapeutics in a note issued to investors on Tuesday, August 13th. Chardan Capital analyst K. Nakae now anticipates that the company will earn ($2.75) per share for the year, down from the previous (…)